VALHALLA, N.Y. - FUJIFILM Holdings America Corporation announced leadership changes across its Life Sciences Group companies, according to a press release statement. The parent company, FUJIFILM Holdings Corporation, maintains a market capitalization of $26 billion and generated revenue of $21.2 billion over the last twelve months.
Tomoyuki Hasegawa will serve as CEO of FUJIFILM Biotechnologies California, a contract development and manufacturing organization for biologics and advanced therapies, while continuing as General Manager of Fujifilm Life Sciences Strategic Office and Chairman and CEO of FUJIFILM Cellular Dynamics. Hasegawa has been with Fujifilm for over 25 years in various leadership roles in Japan and the United States.
Delara Motlagh, Chief Operating Officer of FUJIFILM Cellular Dynamics, will add the title of President to her role. Motlagh joined the company in April 2025 and oversees business, strategy, and execution across the company’s discovery research and cell therapy contract development and manufacturing business units globally. She previously held senior leadership positions at Catalent Pharma Solutions, Terumo Blood and Cell Technologies, and Baxter Healthcare.
David Bolish has been appointed Chief Operating Officer of FUJIFILM Biotechnologies California. Bolish has served as Site Head since 2018 and has more than 20 years of experience in biopharmaceutical manufacturing, engineering, product commercialization, and strategy.
FUJIFILM Cellular Dynamics opened a new headquarters and induced pluripotent stem cell development and manufacturing facility in Madison, Wisconsin, this month. The facility serves the company’s iPSC-based research products and services.
FUJIFILM Biotechnologies California operates a cell therapy manufacturing facility in Thousand Oaks, California, featuring cGMP production suites and quality control laboratories. FUJIFILM Cellular Dynamics develops and manufactures human iPSCs and iPSC-derived cells for drug discovery and contract development services.According to InvestingPro analysis, FUJIFILM Holdings maintains a "GOOD" financial health rating and has paid dividends for 35 consecutive years, demonstrating long-term stability as it expands its life sciences operations.
In other recent news, Fujifilm Holdings Corp reported an operating profit of ¥350.2 billion for the fiscal year ending March 2026. This result exceeded both the company’s guidance of ¥335 billion and the consensus estimate of ¥340 billion, as noted by Citi analysts. Despite this overall positive performance, the company’s fourth-quarter operating profit was ¥101.8 billion, reflecting a 5% decline year-over-year. The decrease in quarterly profit was attributed to the absence of gains from asset sales seen in the previous year, increased silver prices, and one-time expenses related to Bio CDMO operations. These developments highlight the company’s recent financial performance and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates 4901 alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if 4901 is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?